Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.
Platelet MAO activity was measured in 79 Parkinson patients (56 males and 23 females) before and during L-deprenyl therapy. Baseline platelet MAO activity was higher in females than in males with no age dependent differences. During chronic L-deprenyl therapy, MAO activity was inhibited greater than 98%. Four hours after the oral administration of the first 5 mg dose of L-deprenyl, platelet MAO activity was inhibited by 86%. By 24 hours, greater than 98% inhibition was achieved and this degree of inhibition was maintained during continuous L-deprenyl administration. Following oral administration of 10 mg L-deprenyl once a day versus 5 mg L-deprenyl twice a day, the time course of platelet MAO inhibition was similar. Five days after the termination of chronic L-deprenyl therapy, platelet MAO activity was still inhibited by 96%. MAO activity returned to normal by 2 weeks after stopping L-deprenyl. Platelet MAO activity is a useful method of monitoring bioavailability, compliance, dose-response relationship and optimal dosage schedules for L-deprenyl in Parkinson patients.
Lee
D H
DH
Department of Neurology, Mount Sinai School of Medicine, New York City, New York.
Mendoza
M
M
Dvorozniak
M T
MT
Chung
E
E
van Woert
M H
MH
Yahr
M D
MD
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets / Q000201:enzymology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000378:metabolism*; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000627:therapeutic use*; D012737:Sex Factors
D010627:Phenethylamines; D012642:Selegiline; D008995:Monoamine Oxidase